JP2017502091A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017502091A5 JP2017502091A5 JP2016563904A JP2016563904A JP2017502091A5 JP 2017502091 A5 JP2017502091 A5 JP 2017502091A5 JP 2016563904 A JP2016563904 A JP 2016563904A JP 2016563904 A JP2016563904 A JP 2016563904A JP 2017502091 A5 JP2017502091 A5 JP 2017502091A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- combination
- item
- combination according
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims description 17
- 201000011510 cancer Diseases 0.000 claims description 17
- 206010033128 Ovarian cancer Diseases 0.000 claims description 8
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 8
- 206010009944 Colon cancer Diseases 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical group [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 claims description 3
- 239000012661 PARP inhibitor Substances 0.000 claims description 3
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 claims description 3
- 101710179684 Poly [ADP-ribose] polymerase Proteins 0.000 claims description 3
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 claims description 3
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 claims description 3
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 claims description 3
- 208000006468 Adrenal Cortex Neoplasms Diseases 0.000 claims description 2
- 206010004593 Bile duct cancer Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 102000003915 DNA Topoisomerases Human genes 0.000 claims description 2
- 108090000323 DNA Topoisomerases Proteins 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 208000006168 Ewing Sarcoma Diseases 0.000 claims description 2
- 208000017604 Hodgkin disease Diseases 0.000 claims description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 208000005450 Maxillary Sinus Neoplasms Diseases 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 208000026900 bile duct neoplasm Diseases 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 238000012423 maintenance Methods 0.000 claims description 2
- 201000004488 maxillary sinus cancer Diseases 0.000 claims description 2
- 208000019303 maxillary sinus carcinoma Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 229910052697 platinum Inorganic materials 0.000 claims description 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 238000000034 method Methods 0.000 description 13
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461927376P | 2014-01-14 | 2014-01-14 | |
| US61/927,376 | 2014-01-14 | ||
| US201462080775P | 2014-11-17 | 2014-11-17 | |
| US62/080,775 | 2014-11-17 | ||
| PCT/US2015/011239 WO2015108876A1 (en) | 2014-01-14 | 2015-01-13 | Combination-based treatment method |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017502091A JP2017502091A (ja) | 2017-01-19 |
| JP2017502091A5 true JP2017502091A5 (OSRAM) | 2018-01-18 |
| JP6758195B2 JP6758195B2 (ja) | 2020-09-23 |
Family
ID=52469293
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016563904A Active JP6758195B2 (ja) | 2014-01-14 | 2015-01-13 | 併用ベースの治療方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US10653689B2 (OSRAM) |
| EP (1) | EP3094331B1 (OSRAM) |
| JP (1) | JP6758195B2 (OSRAM) |
| KR (1) | KR102501566B1 (OSRAM) |
| AU (1) | AU2015206667B2 (OSRAM) |
| CA (1) | CA2934552C (OSRAM) |
| MX (1) | MX386070B (OSRAM) |
| WO (1) | WO2015108876A1 (OSRAM) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102611382B1 (ko) | 2018-09-19 | 2023-12-07 | 삼성디스플레이 주식회사 | 터치 감지 유닛과 그를 포함하는 표시 장치 |
| WO2025186213A1 (en) | 2024-03-04 | 2025-09-12 | Debiopharm International S.A. | Combination of a wee1 inhibitor and a topoisomerase 1 inhibitor |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT1675622T (lt) * | 2003-09-17 | 2017-09-11 | Nektar Therapeutics | Daugiašakio polimero provaistai |
| RU2361592C2 (ru) | 2004-09-22 | 2009-07-20 | Пфайзер Инк. | Терапевтические комбинации, содержащие ингибитор поли(адф-рибоза)полимеразы |
| JP2006124351A (ja) * | 2004-11-01 | 2006-05-18 | Yakult Honsha Co Ltd | 徐放性抗腫瘍剤組成物 |
| EP2329818A1 (en) * | 2006-01-17 | 2011-06-08 | Abbott Laboratories | Combination therapy with PARP inhibitors |
| TWI426905B (zh) | 2006-02-09 | 2014-02-21 | Enzon Pharmaceuticals Inc | 用於乳癌、大腸直腸癌、胰臟癌、卵巢癌及肺癌之治療的７-乙基-１０羥喜樹鹼之多臂聚合性共軛物 |
| EP2038654A4 (en) * | 2006-06-12 | 2010-08-11 | Bipar Sciences Inc | METHOD FOR THE TREATMENT OF DISEASES WITH PARP INHIBITORS |
| NZ586125A (en) | 2007-11-12 | 2012-12-21 | Bipar Sciences Inc | Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents |
| CA2708157A1 (en) * | 2007-12-07 | 2009-06-11 | Bipar Sciences, Inc. | Treatment of cancer with combinations of topoisomerase inhibitors and parp inhibitors |
| AU2010321882B2 (en) | 2009-11-18 | 2016-01-14 | Nektar Therapeutics | Salt form of a multi-arm polymer-drug conjugate |
| AU2013202947B2 (en) | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
-
2015
- 2015-01-13 KR KR1020167020229A patent/KR102501566B1/ko active Active
- 2015-01-13 WO PCT/US2015/011239 patent/WO2015108876A1/en not_active Ceased
- 2015-01-13 US US15/111,065 patent/US10653689B2/en active Active
- 2015-01-13 MX MX2016009167A patent/MX386070B/es unknown
- 2015-01-13 CA CA2934552A patent/CA2934552C/en active Active
- 2015-01-13 EP EP15704116.1A patent/EP3094331B1/en not_active Revoked
- 2015-01-13 JP JP2016563904A patent/JP6758195B2/ja active Active
- 2015-01-13 AU AU2015206667A patent/AU2015206667B2/en active Active
-
2020
- 2020-04-15 US US16/849,781 patent/US20200237747A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017506264A5 (OSRAM) | ||
| PH12017500635B1 (en) | Aminopyridyloxypyrazole compounds | |
| JP2016538344A5 (OSRAM) | ||
| CN107427516B8 (zh) | 7-苄基-4-(2-甲基苄基)-2,4,6,7,8,9-六氢咪唑并[1,2-a]吡啶并[3,4-e]嘧啶-5(1h)-酮、其类似物、及其盐、以及它们用于治疗的方法 | |
| UA114277C2 (uk) | Антиангіогенна терапія для лікування раку яєчника | |
| EA201890125A1 (ru) | Новые гидроксисложноэфирные производные, способ их получения и фармацевтические композиции, содержащие их | |
| NZ706836A (en) | Methods of treating cancer | |
| JP2015532292A5 (OSRAM) | ||
| BR112015023705A2 (pt) | composto da fórmula (ia) ou um sal, hidrato, solvato ou forma cristalina farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, composto e método para síntese do composto da fórmula (ia) | |
| MD4643B1 (ro) | Noi compuşi de indolizină, procedeu de obţinere a lor şi compoziţii farmaceutice care le conţin | |
| EP4011871A3 (en) | Processes for preparing oxathiazin-like compounds | |
| Wang et al. | Synthesis and evaluation of 1, 7-diheteroarylhepta-1, 4, 6-trien-3-ones as curcumin-based anticancer agents | |
| RU2018134336A (ru) | Комбинированная терапия сорафенибом или регорафенибом и фосфорамидатным пролекарством троксацитабина | |
| MX2019005144A (es) | Tratamiento de cáncer de mama positivo para her2. | |
| MX2016002795A (es) | Compuestos de triazolona y usos de los mismos. | |
| JP2017510660A5 (OSRAM) | ||
| RU2014141365A (ru) | Способ введения противоопухолевого агента | |
| EA201890764A1 (ru) | Селективные антагонисты nr2b | |
| WO2013023043A3 (en) | Treatment of advanced solid tumors using combination of anti-erbb3 immunotherapy and selected chemotherapy | |
| MX2017000208A (es) | Derivados de quinolizinona como inhibidores de pi3k. | |
| JP2017516827A5 (OSRAM) | ||
| JP2017502091A5 (OSRAM) | ||
| EA027986B9 (ru) | Соединения триазолона и их применение | |
| MX369451B (es) | Formas cristalinas de compuestos basados en 1, 8- naftiridin-4(h)-ona particulares y su uso en el tratamiento de ansiedad y condiciones relacionadas. | |
| JP2014534219A5 (OSRAM) |